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ABSTRACT
Introduction: Perceived difficulties in initiating
insulin in patients with type 2 diabetes (T2D)
may prevent many general practitioners (GPs)
from using insulin even when recommended in
guidelines. This paper describes a Royal
Australian College of General Practitioners
accredited education program on starting
insulin in T2D, and its impact on GPs’
attitudes and behavior.
Methods: A faculty comprising GPs with
diabetes expertise, Credentialed Diabetes Nurse
Educators, and endocrinologist developed and
implemented the education program. The
program content was highly procedure
focussed, emphasizing simple, best-practice
processes for starting insulin therapy and
focussing on multidisciplinary models of care.
The highly interactive format of the workshops
included peer-to-peer learning, in which
education was led by diabetes-experienced GP
educators, as well as case study-based approaches
and small group discussions. GP attendees were
asked to rate their individual confidence and
attitudes at the beginning and end of the
meeting. In addition, participants (n = 220)
from two workshops in 2013 were sent a survey
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3 months after the meeting to gauge the
longer-term impact on their clinical practice.
Results: Since 2008, more than 2500 GPs have
attended the workshops, and report substantial
improvements in confidence; after attending,
more GPs were willing to start insulin within
their practice. Evaluations at 3 months
post-meeting indicate that the increased
confidence was associated with behavioral
changes in the subgroup evaluated at this time
(n = 48). Success of this programwas attributed to
peer-to-peer education, multidisciplinary input,
easily implemented best practice procedures and
checklists for starting insulin, and constant
adjustment of meeting process and content
based on feedback and guideline changes.
Conclusion: A peer-to-peer, interactive GP
education program reduced GPs’ perceptions
of the difficulties of starting insulin in T2D and
achieved changes in attendees’ clinical practice.
This education program offers an effective
approach to overcome the therapeutic inertia
that is too common in diabetes management.
Keywords: Australia; Continuing medical
education; General practitioners; Primary care;
Insulin therapy; Type 2 diabetes mellitus
INTRODUCTION
Approximately 70,000 adult Australians
develop type 2 diabetes (T2D) each year. With
a limited number of diabetes clinics and
endocrinologists, general practitioners (GPs)
will increasingly need to manage T2D patients
on insulin. On average, in a survey of Australian
GP’s, diabetes encounters comprised 67.4% of
chronic health conditions managed [1].
However, many GPs are reluctant to prescribe
insulin [2, 3], even though Australian guidelines
highlight the need for it [4–6]. GPs perceive that
starting insulin is difficult because of
uncertainty about guidelines, lack of time and
limited procedural guidance for managing the
process [7].
Therapeutic inertia in the management of
T2D among GPs is a major concern given the
current and future burden of T2D in Australia
[8, 9], and the importance of achieving
glycemic targets for reducing complications
[10]. Indeed, the National Diabetes Strategy
and Action Plan includes education on insulin
commencement as one of the key actions
needed to achieve goals of preventing and
reducing diabetes-related complications [11].
To address this need, an education program
was developed for Australian GPs aimed at
improving their knowledge, confidence and
attitudes towards starting insulin. This article
describes the development of the program,
the format that contributes to its success and
some recent research into the impact on GP




The program was initiated in 2008 by a number
of the authors (GD, GK, PP, AS, SL, IA, JB, MK)
in conjunction with the sponsor (Sanofi—
Sydney Australia). They then sought assistance
from an accredited continuing medical
education (CME) provider (Vivacity Health,
Sydney Australia), who worked with a faculty
of GPs with diabetes expertise, Credentialed
Diabetes Nurse Educators (CDEs) and an
endocrinologist to develop the content and
format of the educational program. Using
published evidence and their own experience,
the faculty identified the key learning issues for
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GPs around starting insulin and the most
appropriate learning techniques for education.
The content of the workshops focussed on
multidisciplinary models of care, involving
endocrinologists and local CDEs as well as
GPs. A key barrier to GPs starting insulin
therapy is a perception that it is a difficult
process, requiring time and planning [3].
Therefore, the program was highly procedure
focussed, reinforcing a simple, best-practice
process for starting insulin that was both
practical and easily implemented in the
surgery, with or without the aid of a CDE/
practice nurse [7, 12]. The program also
reviewed situations that GPs were likely to
come across once patients were established on
insulin, such as sickness, weight gain, managing
hypoglycemia and travel. Participant learning
was reviewed with pre-workshop questions on
diabetes and insulin management compared
with an identical post-workshop survey for all
participants, and as with the basis of this paper,
sampling at 3 months in a smaller
representative sample. It is beyond the scope
of this article to describe the content fully, but it
covered the range of lifestyle interventions and
oral treatments available in Australia, while
focussing on when and how to initiate insulin
in T2D, including the appropriate use of basal
and premixed insulin.
Key elements of the educational format were:
• Using peer-to-peer group learning The
education was led by diabetes-experienced
GP educators. This approach of using peers
who ‘either know more or know differently’
is an established success factor in physician
education [13]. In addition, learning with GP
colleagues exposes people to variability in
how issues are addressed, enabling
self-reflection and providing support [12].
• Extending invitations to GPs interested and
motivated to learn about insulin therapy A
systematic review of interventions to
change physician performance highlighted
the importance of individuals’ readiness to
change as a determinant of effectiveness
[14]. Therefore, a decision was made to
invite GPs who were interested and
motivated to learn about insulin therapy.
Initially, these GPs were identified through
feedback from the sponsor, but subsequent
meetings have been subscribed to mainly
through word-of-mouth.
• Interactive format The format was highly
interactive, utilizing case study-based
approaches, audience response systems,
small group discussions, and question and
answer sessions with the faculty. Common
questions, when asked by attendees, such as
‘‘what is a safe starting dose of insulin? What
time does a patient inject insulin? and If a
patient travels overseas, what advice do I
give?’’, were incorporated in workshops or
addressed specifically at the Q&A session
incorporated within the workshop format.
The final meeting format is outlined in
Fig. 1. The meetings were facilitated by the
faculty, and attendees were split into groups of
25 (maximum) to optimize interactivity.
Content for this education initiative was
developed by the faculty with the assistance of
an accredited CME provider, and accredited
with 40 Category 1 Royal Australian College of
General Practitioners (RACGP) points. The
sponsor had no input into the content of the
program, but provided an unrestricted
educational grant for the development of
workshop materials, and provided funding for
facility hire, faculty and attendees’
transportation, accommodation, and meals in
accordance with Australian regulations.
The first workshop was held in 2008. Since
then, 41 workshops have been held throughout
Australia, with over 2500 GP participants. The
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attendance was open to any rural, regional as
well as urban GPs who had identified an interest
in insulin management.
Facilitator Training and Ongoing Program
Refinement
GP attendees were asked to rate their individual
confidence and attitudes at the beginning and
end of the meeting, and to evaluate workshop
content and format using an evaluation form.
Faculty members developed a training process
to fine-tune both their delivery of the program
and the meeting content. After each workshop,
the faculty agreed on what needed to be
incorporated or amended for the next meeting
based on facilitator and participant feedback,
and the publication of any new relevant
evidence-based information. For example,
based on attendee’s feedback, changes to
workshop structure included a substitution of
a workshop on ‘‘Setting up a Diabetes Clinic’’ to
Fig. 1 Meeting structure and content overview. T2D type 2 diabetes, GP general practitioner, Q&A question and answer,
CME continuing medical education
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workshops incorporating practical patient
resources to facilitate discussion and
implementation of physical activity and diet
changes in diabetes.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors. Permission was obtained from the
de-identified survey participants.
RESULTS
Measuring the Workshop’s Success
Data from pre- and post-meeting assessments
from 2008 to the end of 2013 showed that GPs’
confidence in starting and up-titrating insulin
improved substantially as a result of the
meeting (n = 1368). Fewer GPs needed to refer
patients to an endocrinologist and more were
willing to start insulin within their practice
with help from CDEs (Fig. 2). However, it was
not clear whether this immediate post-meeting
confidence translated into practice
improvements. Therefore, at the last two
workshops in 2013, participants (n = 220) were
also sent a survey 3 months after the meeting to
gauge the impact of the education on their
clinical practice. Overall, 48 participants
returned completed survey forms (21.8%
response rate); these participants were
representative in sex and area of practice
(urban/rural) of the overall attendees.
Before the meetings, 73% of the 220 GPs
surveyed had a negative perception of insulin
therapy (e.g., too many barriers, can’t manage
patients’ fears). This dropped to 9% after the
meetings, with 91% thinking that managing
patients on insulin was not as hard as they had
thought. This change in attitude persisted after
3 months, as did the improvement in GPs’
confidence to address patient concerns, such
as fear of injections. Moreover, a larger
percentage of GPs reported starting one or
more patients on insulin 3 months after versus












































n = 1368 
Fig. 2 Initiating and up-titrating insulin before and
immediately after meeting survey results: aggregated data
from the 1368 GP attendees. CME continuing medical











































3 months aer meeng (n=48) 
NA = Not applicable. GPs were unable to iniate insulin before the end of the meeng. 
Fig. 3 3-month follow-up cohort: GP conﬁdence, referral
for initiation and actual insulin initiations before and after
the meeting and 3-months post-meeting in patients with
type 2 diabetes. N/A not applicable because this question
was not asked in the immediate post-meeting evaluation,
GP general practitioner
Diabetes Ther (2016) 7:153–161 157
suggesting that this improved confidence
resulted in more initiations (Fig. 3).
DISCUSSION
Emerging evidence has supported use of ‘‘Local
Opinion Leaders’’ and the use of
interprofessional and peer-to peer education in
enabling positive health educational programs
[15–17]. This program achieved its objectives of
reducing GPs’ perceptions of the difficulties of
starting insulin in T2D. Importantly, surveys
conducted 3 months after the last two
workshops in 2013 demonstrate that attendee
confidence is maintained and results in a real
change during clinical practice.
We believe the success of this program can
be attributed to:
• Use of peer-to-peer learning methodology,
which had a positive effect on interaction
and freedom of discussion, and
consequently on meeting outcomes.
• Choice of GP and CDE facilitators In our view,
facilitators need to be experts in the subject
and passionate about it, and good educators,
but open to learning more themselves.
Interestingly, the benefits of peer-to-peer
learning applied as much to the faculty
members as it did to the attendees: the
faculty became more skilled at educating
their peers, and their interest in diabetes
grew. Many faculty members have since
founded the RACGP diabetes special
interest network together.
• Providing content that is easily applied during
clinical practice Previous research has shown
the importance of developing content that is
useful for implementation by GPs in routine
clinical practice. For example, two Canadian
studies of multidisciplinary peer-to-peer
education programs demonstrated success
in increasing and maintaining GP
confidence by including content that was
‘useful and doable in real GP time’ [18, 19].
• Reinforcing a multidisciplinary approach to
diabetes management Many GPs who did not
consider involving a CDE in starting patients
on insulin before the meeting had altered
their opinion by the end, which will help
time-poor GPs to manage their patients on
insulin. It also helped to clarify the roles of
the various health professionals involved in
managing T2D.
• Keeping the content relevant, interesting and
up-to-date Having an efficient, workable
process in place to refine both the content
and its delivery that takes into account
meeting feedback and changes to clinical
practice is crucial to maintaining the
relevance and quality of the program [20].
A key limitation of this analysis is that the
impact of education on 3-month outcomes was
only examined in recent cohorts of attendees,
and only 21.8% of these attendees responded to
the 3-month evaluation. While this response
rate is somewhat disappointing, it is higher
than the 16.3% rate reported in a recent study
of responses to surveys among Australian GPs
[21]. Since the 3-month evaluation will be
conducted at all subsequent workshops, there
is an opportunity to accumulate further data on
the medium-term impact on attendee behavior,
as well as to integrate initiatives to improve
response rates to the 3-month evaluation. The
program did not aim to assess any long-term
effects on GP practice or patient health
outcomes.
CONCLUSIONS
This education program addressed an important
need in Australian general practice—to educate
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GPs about starting insulin, and thereby
overcome the therapeutic inertia that is too
common in diabetes management. It was
developed by a passionate multidisciplinary
faculty who set out to deliver a program that
would change GP behavior in relation to insulin
initiation. The recent data collected 3 months
post-workshop attest to its success in achieving
this goal. Even after 7 years, each workshop
continues to be fully subscribed to, and the
faculty is committed to continuous
improvement based on feedback and changes
in evidence-based guidelines.
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